SalvaRx is a cancer immunotherapy specialist. The group plans to build a portfolio of oncology products in this promising new area of cancer treatment, where recent discoveries have led to a step change improvement in clinical outcomes.
18 Apr 2016
A cancer immunotherapy specialist
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
A cancer immunotherapy specialist
Salvarx Group (SALV:LON) | 0 0 (-8.6%) | Mkt Cap: 6.74m
- Published:
18 Apr 2016 -
Author:
Vadim Alexandre -
Pages:
25 -
SalvaRx is a cancer immunotherapy specialist. The group plans to build a portfolio of oncology products in this promising new area of cancer treatment, where recent discoveries have led to a step change improvement in clinical outcomes.